FeesSafety
Pluang+

Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition

Analyst Insights
18 Nov 2026, 18:57 WIB
Seeking Alpha
View Source
Bullish
Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition

Novo Nordisk updated its 2026 free cash flow guidance to 60–70 billion DKK, supported by lower capital expenditure and a diversified product pipeline including the Wegovy pill. The company expects adjusted sales and operating profit to grow modestly or decline slightly, reflecting cautious mid-single-digit growth amid pricing pressures and competition. The looming 2032 patent expiration of semaglutide poses a sales risk, but expansion into cardiovascular and liver diseases and multiple upcoming product launches aim to sustain growth. The intrinsic valuation stands at 393.21 DKK, with faster growth seen as potential upside rather than certainty.

Novo Nordisk shares are currently trading at USD 39.51 on Pluang, down 2.92% in the last day. The stock has a dividend yield of 4.41% and a market cap of $178.63 billion as of Nov 19, 2026 00:11 WIB.

More News (NVO)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App